Hyperimmune IV Immunoglobulin Treatment

Hung, Ivan; To, Kelvin Kai-Wang; Lee, Cheuk-Kwong; Lee, Kar-Lung; Yan, Wei; Chan, Kenny; Chan, Wan Mui; Ngai, Chun-Wai; Law, Kin-Ip; Chow, Fu-Loi; Liu, Raymond; Lai, Kang-Yiu; Lau, Candy C. Y.; Liu, Shao-Haei; Chan, Kwok‐Hung; Lin, Che-Kit; Yuen, Kwok‐Yung

doi:10.1378/chest.12-2907

Cited by 271 publications

(110 citation statements)

References 27 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…Our previous studies showed that convalescent blood products with high MN titers can improve the outcome of patients with severe A(H1N1)pdm09 infection (26,27). In the current study, the passive transfer of convalescent-phase sera with neutralizing activity detectable only by FFMN assay, but not by the standard MN assay, did not exhibit a significant in vivo protective effect for mice challenged with the A(H7N9) virus.…”

Section: Discussionmentioning

confidence: 99%

Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes

Lee

Zhu

Zhang

et al. 2015

Clin. Vaccine Immunol.

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes

Lee

Zhu

Zhang

et al. 2015

Clin. Vaccine Immunol.

Self Cite

View full text Add to dashboard Cite

“…Intravenous immunoglobulin91011 and influenza-specific monoclonal antibodies (mAbs), particularly those that bind to the conserved, stem region of the haemagglutinin (HA)121314, are also being considered as alternative treatments. mAbs that inhibit the enzyme activity of NA also have the potential to serve as therapeutic agents15161718.…”

mentioning

confidence: 99%

Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers

et al. 2015

View full text Add to dashboard Cite

A(H1N1)pdm09 influenza A viruses predominated in the 2013–2014 USA influenza season, and although most of these viruses remain sensitive to Food and Drug Administration-approved neuraminidase (NA) inhibitors, alternative therapies are needed. Here we show that monoclonal antibody CD6, selected for binding to the NA of the prototypic A(H1N1)pdm09 virus, A/California/07/2009, protects mice against lethal virus challenge. The crystal structure of NA in complex with CD6 Fab reveals a unique epitope, where the heavy-chain complementarity determining regions (HCDRs) 1 and 2 bind one NA monomer, the light-chain CDR2 binds the neighbouring monomer, whereas HCDR3 interacts with both monomers. This 30-amino-acid epitope spans the lateral face of an NA dimer and is conserved among circulating A(H1N1)pdm09 viruses. These results suggest that the large, lateral CD6 epitope may be an effective target of antibodies selected for development as therapeutic agents against circulating H1N1 influenza viruses.

show abstract

“…Historically, passive transfer of convalescent human sera has been a viable option as a functional therapy in situations of crisis (1,2). According to reports, passive transfer techniques were implemented for influenza virus infection from as early as the 1918 pandemic to as recently as the H1N1 pandemic and exhibited good results (3)(4)(5). Immunotherapy with monoclonal antibodies (MAbs) is the only approved treatment for prophylactic use in children at risk of respiratory syncytial virus infection (6).…”

mentioning

confidence: 99%

Direct Administration in the Respiratory Tract Improves Efficacy of Broadly Neutralizing Anti-Influenza Virus Monoclonal Antibodies

Leyva-Grado

Tan

Leon

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The emergence of influenza virus strains resistant to approved neuraminidase inhibitors and the time constrains after infection when these drugs can be effective constitute major drawbacks for this class of drugs. This highlights a critical need to discover new therapeutic agents that can be used for the treatment of influenza virus-infected patients. The use of broadly neutralizing anti-influenza monoclonal antibodies (MAbs) has been sought as an alternative immunotherapy against influenza infection. Here, we tested in mice previously characterized broadly neutralizing anti-hemagglutinin (HA) stalk MAbs prophylactically and therapeutically using different routes of administration. The efficacy of treatment against an influenza H1N1 pandemic virus challenge was compared between two systemic routes of administration, intraperitoneal (i.p.) and intravenous (i.v.), and two local routes, intranasal (i.n.) and aerosol (a.e.). The dose of MAb required for prophylactic protection was reduced by 10-fold in animals treated locally (i.n. or a.e.) compared with those treated systemically (i.p. or i.v.). Improved therapeutic protection was observed in animals treated i.n. on day 5 postinfection (60% survival) compared with those treated via the i.p. route (20% survival). An increase in therapeutic efficacy against other influenza virus subtypes (H5N1) was also observed when a local route of administration was used. Our findings demonstrate that local administration significantly decreases the amount of broadly neutralizing monoclonal antibody required for protection against influenza, which highlights the potential use of MAbs as a therapeutic agent for influenza-associated disease.

show abstract

Hyperimmune IV Immunoglobulin Treatment

Cited by 271 publications

References 27 publications

Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes

Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes

Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers

Direct Administration in the Respiratory Tract Improves Efficacy of Broadly Neutralizing Anti-Influenza Virus Monoclonal Antibodies

Contact Info

Product

Resources

About